ArticleBioinformatics (Oxford, England)2026
Informative relational learning for adverse reaction prediction with enhanced generalization to novel drugs.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
motivationAccurate prediction of adverse drug reactions (ADRs) is essential for drug safety surveillance, and recent advances in machine learning with heterogeneous biomedical information have improved predictive performance. However, two challenges remain: current methods often learn inadequate ADR representations that fail to capture dependencies among ADRs, and generalize poorly to novel drugs.
resultsTo obtain informative ADR embeddings, we construct a multi-source, multi-relational ADR graph that integrates hierarchical structure and empirical ADR co-occurrence, and apply a relational graph convolutional network (R-GCN) to learn relation-aware ADR representations. To enhance generalization to novel drugs, we exploit the hierarchical structure of the Anatomical Therapeutic Chemical (ATC) classification to link drugs via shared higher-level categories for effective knowledge transfer and model these relations with an R-GCN. We further introduce a Conditional Domain Adversarial Network (CDAN) to reduce distribution shifts between known and novel drugs by aligning features conditioned on predicted ADR labels, learning domain-invariant yet task-relevant representations. Additionally, to exploit similar ADR patterns among related drugs, we introduce a dual-branch mixture-of-experts (Dual-MoE) module where each expert captures ADR commonalities within a drug category in one branch, while a separate branch models global patterns. Extensive experiments show that our method consistently outperforms seven baselines, achieving F1 improvements of 4.3% and 4.7% over the best baseline on two datasets, respectively, with more balanced precision-recall trade-offs. It also improves AUC on uncommon ADRs by 7% more than on common ADRs, and remains more robust under data sparsity, with more gradual performance degradation as training data decreases. AVAILABILITY AND IMPLEMENTATION: The code of our model is available at https://github.com/fzsdb/Knowledge-guided-ADR-prediction.git.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.